

Nucleosides, Nucleotides and Nucleic Acids

Publication details, including instructions for authors and subscription information:

<http://www.tandfonline.com/loi/lncn20>

Synthesis and Anti-HIV Activity of 4'-Cyano-2',3'-didehydro-3'-deoxythymidine

Kazuhiro Haraguchi Ph.D.^a, Yoshiharu Itoh^{a d}, Shingo Takeda^a, Yosuke Honma^a,
Hiromichi Tanaka^a, Takao Nitanda^b, Masanori Baba^b, Ginger E. Dutschman^c &
Yung-Chi Cheng^c

^a School of Pharmaceutical Sciences, Showa University, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo, 142-8555, Japan

^b Center for Chronic Viral Diseases, Division of Human Retroviruses, Faculty of Medicine, Kagoshima University, 8-35-1 Sakuragaoka, Kagoshima, 890-8520, Japan

^c Department of Pharmacology, School of Medicine, Yale University, 333 Cedar street, New Haven, Connecticut, 06520, USA

^d Central Pharmaceutical Research Institute, Japan Tobacco Inc., Takatsuki, Osaka, Japan

Published online: 07 Feb 2007.

To cite this article: Kazuhiro Haraguchi Ph.D., Yoshiharu Itoh, Shingo Takeda, Yosuke Honma, Hiromichi Tanaka, Takao Nitanda, Masanori Baba, Ginger E. Dutschman & Yung-Chi Cheng (2004) Synthesis and Anti-HIV Activity of 4'-Cyano-2',3'-didehydro-3'-deoxythymidine, *Nucleosides, Nucleotides and Nucleic Acids*, 23:4, 647-654, DOI: [10.1081/NCN-120030721](https://doi.org/10.1081/NCN-120030721)

To link to this article: <http://dx.doi.org/10.1081/NCN-120030721>

PLEASE SCROLL DOWN FOR ARTICLE

Taylor & Francis makes every effort to ensure the accuracy of all the information (the "Content") contained in the publications on our platform. However, Taylor & Francis, our agents, and our licensors make no representations or warranties whatsoever as to the accuracy, completeness, or suitability for any purpose of the Content. Any opinions and views expressed in this publication are the opinions and views of the authors, and are not the views of or endorsed by Taylor & Francis. The accuracy of the Content should not be relied upon and should be independently verified with primary sources of information. Taylor and Francis shall not be liable for any losses, actions, claims, proceedings, demands, costs, expenses, damages, and other liabilities whatsoever or howsoever caused arising directly or indirectly in connection with, in relation to or arising out of the use of the Content.

This article may be used for research, teaching, and private study purposes. Any substantial or systematic reproduction, redistribution, reselling, loan, sub-licensing, systematic supply, or distribution in any form to anyone is expressly forbidden. Terms & Conditions of access and use can be found at <http://www.tandfonline.com/page/terms-and-conditions>

Synthesis and Anti-HIV Activity of 4'-Cyano-2',3'-didehydro-3'-deoxythymidine

Kazuhiro Haraguchi,^{1,*} Yoshiharu Itoh,^{1,#} Shingo Takeda,¹
Yosuke Honma,¹ Hiromichi Tanaka,¹ Takao Nitanda,² Masanori Baba,²
Ginger E. Dutschman,³ and Yung-Chi Cheng³

¹School of Pharmaceutical Sciences, Showa University, Shinagawa-ku,
Tokyo, Japan

²Center for Chronic Viral Diseases, Division of Human Retroviruses,
Faculty of Medicine, Kagoshima University, Kagoshima, Japan

³Department of Pharmacology, School of Medicine, Yale University, New Haven,
Connecticut, USA

ABSTRACT

A new anti-HIV agent 4'-cyano-2',3'-didehydro-3'-deoxythymidine (**9**) was synthesized by allylic substitution of the 3',4'-unsaturated nucleoside **14**, having a leaving group at the 2'-position, with cyanotrimethylsilane in the presence of SnCl₄. Evaluation of the anti-HIV activity of **9** showed that this compound is much less potent than the recently reported 2',3'-didehydro-3'-deoxy-4'-(ethynyl)thymidine (**1**).


Key Words: Anti-HIV; Cyano; Didehydro-3'-deoxythymidine; Unsaturated-sugar nucleoside; Phenylselenide anion; Allylic substitution; Organosilicon reagent.

*Correspondence: Kazuhiro Haraguchi, Ph.D., School of Pharmaceutical Sciences, Showa University, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo 142-8555, Japan; E-mail: harakazu@pharm.showa-u.ac.jp.

#Current address: Yoshiharu Itoh, Central Pharmaceutical Research Institute, Japan Tobacco Inc., Takatsuki, Osaka, Japan.

INTRODUCTION

During our recent studies on the reaction of organometallic reagents with 4',5'-epoxy nucleosides,^[1] 2',3'-didehydro-3'-deoxy-4'-(ethynyl)thymidine (**1**) was synthesized.^[2] Biological evaluation of **1** revealed that this compound is a more potent anti-HIV agent than the parent compound stavudine (**2**).^[2-6] This finding was quite unexpected, since it has been reported that removal of the 3'-hydroxyl group in the anti-HIV active 4'-azidothymidine (**3**) leads to complete loss of the activity: compounds **4** and **5** are devoid of the activity.^[7] An additional advantage of **1** is the fact that this compound is less toxic to CEM cell growth and less inhibitory to mitochondrial DNA synthesis than stavudine (**2**).




As a result of our brief examination of structure-activity relationship (SAR) of 4'-carbon-substituted 2',3'-didehydro-3'-deoxythymidine derivatives, it became apparent that the introduction of a methyl or vinyl group at the 4'-position leads to complete loss of the activity (**6**^[8] and **7**),^[2] and that alkylation of the ethynyl group of **1** is also discouraging (for example, **8**). From these results, one would readily expect that suitable 4'-substituents should possess an sp-hybridized carbon atom, and its size should be as small as possible. We describe here the synthesis and anti-HIV activity of 4'-cyano-2',3'-didehydro-3'-deoxythymidine (**9**) motivated by the above considerations.

RESULTS AND DISCUSSION

Nucleosides having a cyano group at the 4'-position have mostly been synthesized by manipulation of the respective 4'-hydroxymethyl precursors.^[9] In 1996, an allylic substitution of 3',4'-unsaturated nucleosides having a leaving group at the 2'-position was reported from our laboratory.^[10] This method provides a new entry to the synthesis of 4'-branched 2',3'-didehydro-2',3'-dideoxyribonucleosides. Also reported in this paper is the fact that, irrespective of the stereochemistry ("up" or "down") of the 2'-leaving group, incoming nucleophiles attack the 4'-position from both the α - and β -faces, presumably due to the intervention of an oxonium intermediate. Since organosilicon reagents, including cyanotrimethylsilane, can be used as nucleophiles in combination with SnCl₄, this methodology was used for the present purpose.


Preparation of the 3',4'-unsaturated thymine nucleoside **14**, to be used as a substrate for the allylic substitution, is shown in Scheme 1. Thus, 1-(β -D-ribofuranosyl)thymine was converted to the 2',3'-epoxide **10** according to the published procedure.^[11] Cleavage of the epoxide ring was conducted by reacting with a phenylselenide anion





Scheme 1. Preparation of the 3',4'-unsaturated thymine nucleoside.

prepared by reducing (PhSe)₂ with LiAlH₄^[12] (in dioxane, for 2 h at room temperature) to give the desired 3'-phenylseleno derivative (**11**, 56%) as well as its 2'-isomer (**12**, 42%). The 5'-*O*-trityl group of **11** was replaced with *tert*-butyldiphenylsilyl group from the expectation that the anisotropic effect of this silyl protecting group would serve as a stereochemical determinant of the 4'-substituted products at a later stage. Further



Scheme 2. 3',4'-Unsaturated thymine nucleoside reacting with cyanotrimethylsilane.

Table 1. Anti-HIV-1 activity in MT-2 cells.^a

Compound	IC ₅₀ (μM) ^b	CC ₅₀ (μM) ^c
9	7.0 ± 2.6	>100
1	0.25 ± 0.14	>100
Stavudine (2)	1.3 ± 0.4	>100

^aData represent mean values for two separate experiments.

^bInhibitory concentration required to achieve 50% protection of MT-2 cells against the cytopathic effect of HIV-1.

^cCytotoxic concentration required to reduce the viability of mock-infected MT-2 cells by 50%.

acetylation of the 2'-hydroxyl group gave **13**. Oxidation of **13** with *m*-CPBA gave the corresponding selenoxide in 70% yield. Subsequent elimination of benzeneselenenic acid was carried out in THF at 70°C for 1 h in the presence of *i*-Pr₂NEt. Despite the presence of two *syn*-hydrogens (H-2' and H-4') available for the elimination, exclusive removal of the H-4' was observed in this reaction to give the 3',4'-unsaturated derivative **14** as the sole product in 67% yield.

When **14** was reacted with cyanotrimethylsilane (10 equiv.) in the presence of SnCl₄ (5 equiv.) in CH₂Cl₂ at -70°C for 5 h, no S_N2 product was formed. Instead two isomeric products **15** (48%) and **16** (43%) resulting from allylic substitution were isolated as shown in Scheme 2. The depicted stereochemistry of **15** at the 4'-position was deduced from the ¹H NMR observation that its 5-Me resonance appeared at a significantly higher field of δ 1.53 when compared with that of **16** (δ 1.95) or **14** (δ 1.92), due to the anisotropic effect of the phenyl ring in the 5'-*O*-protecting group. Finally, removal of the 5'-*O*-silyl group in **15** was carried out with Bu₄NF in THF to give the desired 4'-cyano analogue **9** in almost quantitative yield.

Compound **9** thus synthesized was assayed for its ability to inhibit the replication of HIV-1 in MT-2 cell culture by the reported procedure.^[13] In Table 1 are shown the assay results of **9** together with those of **1** and the parent compound stavudine (**2**). Although the 4'-cyano analogue (**9**) was found to be active as we anticipated, its activity is almost five times lower than that of stavudine (**2**). Further SAR studies on this class of compounds are currently under investigation in our laboratory.

EXPERIMENTAL SECTION

Melting points are uncorrected. ¹H NMR and ¹³C NMR were measured on a JEOL JNM-LA 500 (500 MHz). Chemical shifts are reported relative to Me₄Si. Mass spectra (MS) were taken in FAB mode with *m*-nitrobenzyl alcohol as a matrix on a JEOL JMS-700. Ultraviolet spectra (UV) were recorded on a JASCO V-530 spectrophotometer. Column chromatography was carried out on silica gel (Micro Bead Silica Gel PSQ 100B, Fuji Silysia Chemical Ltd.). Thin layer chromatography (TLC) was performed on silica gel (precoated silica gel plate F₂₅₄, Merck). Where necessary, analytical samples were purified by high-performance liquid chromatography (HPLC). HPLC was carried



out on a Shimadzu LC-6AD with a Shim-pack PREP-SIL (H) KIT column (2 × 25 cm). THF was distilled from benzophenone ketyl.

1-[2,3-Anhydro-5-*O*-trityl-β-D-lyxofuranosyl]thymine (10). To a pyridine (30 mL) suspension of 1-(β-D-ribofuranosyl)thymine (5.16 g, 20 mmol) was added TrCl (6.69 g, 24 mmol) at 0°C under Ar atmosphere, and the reaction mixture was stirred at rt overnight. To this was added MsCl (4.6 mL, 60 mL), and the mixture was stirred at 0°C for 5 h. The reaction mixture was quenched by adding ice chips and then partitioned between CHCl₃/H₂O (200 mL × 2/100 mL). Column chromatography (4% MeOH in CH₂Cl₂) of the organic layer gave 1-(2,3-di-*O*-mesyl-5-*O*-trityl-β-D-ribofuranosyl)thymine, which was dissolved in EtOH (200 mL). To the EtOH solution of the product was added 1 M NaOH (200 mL), and the mixture was stirred at refluxing temperature for 2 h. The reaction mixture was neutralized with 1 M HCl, evaporated to dryness, and partitioned between EtOAc/H₂O (200 mL/50 mL × 4). Column chromatography (hexane/EtOAc = 1/4) of the organic layer gave **10** (3.80 g, 39%) as a solid: mp 174–175°C; ¹H NMR (CDCl₃) δ 1.83 (3H, d, *J*_{5-Me,6} = 1.3 Hz, 5-Me), 3.39 (1H, dd, *J*_{5'a,5'b} = 9.7 and *J*_{4',5'a} = 5.5 Hz, H-5'), 3.49 (1H, dd, *J*_{5'a,5'b} = 9.7 and *J*_{4',5'b} = 5.9 Hz, H-5'), 3.87 (1H, dd, *J*_{3',4'} = 0.8 and *J*_{2',3'} = 2.8 Hz, H-3'), 3.91 (1H, dd, *J*_{1',2'} = 0.7 and *J*_{2',3'} = 2.8 Hz, H-2'), 4.14–4.17 (1H, m, H-4'), 6.19 (1H, d, *J*_{1',2'} = 0.7 Hz, H-1'), 7.24–7.33 (9H, m, Tr), 6.98 (1H, d, *J*_{5-Me,6} = 1.3 Hz, H-6), 7.46–7.49 (6H, m, Tr), 8.61 (1H, br NH); FAB-MS (*m/z*) 483 (M⁺ + H).

1-(3-Deoxy-3-phenylseleno-5-*O*-trityl-β-D-arabinofuranosyl)thymine (11) and 1-(2-Deoxy-2-phenylseleno-5-*O*-trityl-β-D-xylofuranosyl)thymine (12). To a dioxane (20 mL) suspension of the phenylselenide anion,^[12] prepared from (PhSe)₂ (3.94 g, 12.61 mmol) and LiAlH₄ (359 mg, 9.46 mmol), was added **10** (3.80 g, 7.88 mmol) dissolved in dioxane (20 mL), and the mixture was stirred at rt for 2 h under Ar atmosphere. Neutralization of the reaction mixture with AcOH followed by column chromatography (hexane/EtOAc = 1/2) gave **11** (2.82 g, 56%, foam) and **12** (2.12 g, 42%, foam).

Physical data of **11**: ¹H NMR (CDCl₃, after addition of D₂O) δ 2.05 (3H, s, 5-Me), 3.43 (1H, dd, *J*_{5'a,5'b} = 11.0 and *J*_{4',5'a} = 3.6 Hz, H-5'), 3.59–3.65 (2H, m, H-5' and H-3'), 3.97–4.01 (1H, m, H-4'), 4.48 (1H, dd, *J*_{2',3'} = 5.4 and *J*_{1',2'} = 5.2 Hz, H-2'), 6.05 (1H, d, *J*_{1',2'} = 5.2 Hz, H-1'), 7.21–7.32, 7.32–7.38 and 7.46–7.53 (20H, each as m, Tr and SePh), 7.71 (1H, s, H-6); FAB-MS (KI, *m/z*) 679 (M⁺ + K).

Physical data of **12**: ¹H NMR (CDCl₃, after addition of D₂O) δ 1.65 (3H, d, *J*_{5-Me,6} = 1.2 Hz, 5-Me), 3.51 (1H, dd, *J*_{5'a,5'b} = 10.6 and *J*_{4',5'a} = 4.0 Hz, H-5'), 3.58 (1H, dd, *J*_{5'a,5'b} = 10.6 and *J*_{4',5'b} = 4.4 Hz, H-5'), 3.76 (1H, dd, *J*_{3',4'} = 4.6 and *J*_{2',3'} = 3.2 Hz, H-3'), 4.23–4.25 (1H, m, H-4'), 4.29 (1H, dd, *J*_{2',3'} = 3.2 and *J*_{1',2'} = 4.4 Hz, H-2'), 6.01 (1H, d, *J*_{1',2'} = 4.4 Hz, H-1'), 7.25–7.34, 7.41–7.44 and 7.61–7.63 (21H, each as m, Tr and SePh), 6.98 (1H, d, *J*_{5-Me,6} = 1.3 Hz, H-6); FAB-MS (KI, *m/z*) 679 (M⁺ + K).

1-[2-*O*-Acetyl-5-*O*-(*tert*-butyldiphenylsilyl)-3-deoxy-3-phenylseleno-β-D-arabinofuranosyl]thymine (13). An 80% AcOH (40 mL) solution of **11** (1.67 g, 2.61 mmol) was stirred at 80°C for 1 h. Evaporation of the reaction mixture followed by column chromatography (3% MeOH in CH₂Cl₂) gave 1-(3-deoxy-3-phenylseleno-β-D-arabinofuranosyl)thymine (0.57 g, 55%) as a syrup. To a pyridine (7 mL) solution of this



product (563.9 mg, 1.42 mmol) was added *t*-butyldiphenylsilyl chloride (0.55 mL, 2.13 mmol). After stirring overnight at rt, the reaction mixture was quenched with EtOH and evaporated to dryness. Column chromatography (hexane/AcOEt = 1/4) of the residue gave 1-[5-*O*-(*tert*-butyldiphenylsilyl)-3-deoxy-3-phenylseleno- β -D-arabinofuranosyl]thymine (675.8 mg, 75%) as a syrup. A mixture of this product (633.4 mg, 1.0 mmol), *i*-Pr₂NEt (0.52 mL, 3.0 mmol), Ac₂O (0.19 mL, 2.0 mmol), and DMAP (24.4 mg, 0.2 mmol) in CH₂Cl₂ (10 mL) was stirred at rt for 1 h. The reaction mixture was partitioned between CHCl₃/sat. NaHCO₃ (150 mL \times 2/50 mL). Column chromatography (hexane/EtOAc = 1/1) of the organic layer gave **13** (599.3 mg, 88%) as a foam: ¹H NMR (CDCl₃) δ 1.09 (9H, s, *t*-Bu), 1.65 (3H, s, 5-Me), 1.89 (3H, s, Ac), 3.82 (1H, dd, $J_{3',4'} = 8.6$ and $J_{2',3'} = 6.0$ Hz, H-3'), 3.89–3.95 (2H, m, H-5'), 4.01–4.04 (1H, m, H-4'), 5.54 (1H, dd, $J_{2',3'} = 6.0$ and $J_{1',2'} = 5.2$ Hz, H-2'), 6.09 (1H, d, $J_{1',2'} = 5.2$ Hz, H-1'), 7.29–7.48, 7.59–7.67 (16H, each as m, SiPh, SePh, and H-6), 8.18 (1H, br, NH); FAB-MS (m/z) 679 (M^+ + H), 621 (M^+ - *t*-Bu).

1-[2-*O*-Acetyl-5-*O*-(*tert*-butyldiphenylsilyl)- β -L-glycero-pent-3-enofuranosyl]thymine (14). To a CH₂Cl₂ (8 mL) solution of **13** (563.8 mg, 0.83 mmol) was added *m*-CPBA (172.6 mg, 1.0 mmol) in CH₂Cl₂ (4 mL) at 0°C, and the mixture was stirred for 30 min. The reaction mixture was neutralized with Et₃N and partitioned between CHCl₃/sat. NaHCO₃ (150 mL \times 3/50 mL). Column chromatography (3% MeOH in CH₂Cl₂) of the organic layer gave the corresponding selenoxide (403.4 mg, 70%) as a foam. A mixture of this selenoxide (372.3 mg, 0.54 mmol) and *i*-Pr₂NEt (0.74 mL, 1.61 mmol) in THF (7 mL) was stirred at 70°C under Ar atmosphere for 1 h. Evaporation of the reaction mixture followed by column chromatography (hexane/EtOAc = 2/1) gave **14** (188.4 mg, 67%) as a foam: ¹H NMR (CDCl₃) δ 1.09 (9H, s, *t*-Bu), 1.92 (3H, d, $J_{5\text{-Me},6} = 1.2$ Hz, 5-Me), 1.95 (3H, s, Ac), 4.27 (1H, ddd, $J_{5'a,5'b} = 15.0$ and $J_{2',5'a} = J_{3',5'a} = 1.6$ Hz, H-5'), 4.32 (1H, ddd, $J_{5'a,5'b} = 15.0$ and $J_{2',5'b} = J_{3',5'b} = 1.2$ Hz, H-5'), 5.29–5.30 (1H, m, H-3'), 5.83 (1H, m, H-2'), 6.66 (1H, d, $J_{1',2'} = 7.2$ Hz, H-1'), 7.01 (1H, q, $J_{5\text{-Me},6} = 1.2$ Hz, H-6), 7.39–7.49 and 7.66–7.70 (10H, m, SiPh), 8.20 (1H, br, NH); FAB-MS (m/z) 521 (M^+ + H) and 463 (M^+ - *t*-Bu).

5'-*O*-(*tert*-Butyldiphenylsilyl)-4'-cyano-2',3'-didehydro-3'-deoxythymidine (15) and Its 4'-epimer (16). To a CH₂Cl₂ (3.5 mL) solution of **14** (52.1 mg, 0.1 mmol) was added Me₃SiCN (0.13 mL, 1.0 mmol) and then SnCl₄ (0.5 mL, 0.5 mmol) at -70°C under Ar atmosphere. After being stirred at -70°C for 5 h, the reaction mixture was partitioned between CHCl₃/sat. NaHCO₃ (60 mL \times 3/20 mL). Purification of the organic layer by preparative TLC (hexane/AcOEt = 1/1) gave **15** (23.3 mg, 48%, syrup) and **16** (20.8 mg, 43%, syrup). Physical data of **15**: ¹H NMR (CDCl₃) δ 1.11 (9H, s, *t*-Bu), 1.53 (3H, d, $J_{5\text{-Me},6} = 1.2$ Hz, 5-Me), 3.94 (1H, d, $J_{5'a,5'b} = 11.2$ Hz, H-5'), 4.04 (1H, d, $J_{5'a,5'b} = 11.2$ Hz, H-5'), 6.15 (1H, dd, $J_{1',3'} = 1.2$ and $J_{2',3'} = 6.0$ Hz, H-3'), 6.39 (1H, dd, $J_{1',2'} = 2.0$ and $J_{2',3'} = 6.0$ Hz, H-2'), 6.80 (1H, d, $J_{5\text{-Me},6} = 1.2$ Hz, H-6), 7.23 (1H, dd, $J_{1',3'} = 1.2$ and $J_{1',2'} = 2.0$ Hz, H-1'), 7.37–7.49 and 7.62–7.67 (10H, each as m, SiPh), 8.87 (1H, br, NH); FAB-MS (m/z) 488 (M^+ + H). Physical data of **16**: ¹H NMR (CDCl₃) δ 1.09 (9H, s, *t*-Bu), 1.95 (3H, d, $J_{5\text{-Me},6} = 1.2$ Hz, 5-Me), 3.77 (1H, d, $J_{5'a,5'b} = 10.0$ Hz, H-5'), 3.93 (1H, d, $J_{5'a,5'b} = 10.0$ Hz, H-5'), 6.13 (1H, dd, $J_{1',3'} = 1.8$ and $J_{2',3'} = 6.0$ Hz, H-3'), 6.40 (1H, dd, $J_{1',2'} = 1.8$ and $J_{2',3'} = 6.0$ Hz, H-2'),



6.99 (1H, d, $J_{5\text{-Me},6} = 1.2$ Hz, H-6), 7.10 (1H, t, $J_{1',2'} = J_{1',3'} = 1.8$ Hz, H-1'), 7.40–7.49 and 7.63–7.67 (10H, each as m SiPh), 8.75 (1H, br, NH); FAB-MS (m/z) 488 ($M^+ + H$).

4'-Cyano-2',3'-didehydro-3'-deoxythymidine (9). To a THF (4 mL) solution of **15** (48.1 mg, 0.099 mmol) was added $\text{Bu}_4\text{NF} \cdot 3\text{H}_2\text{O}$ (39.2 mg, 0.15 mmol) at 0°C , and the mixture was stirred at rt for 1 h. Evaporation of the reaction mixture followed by column chromatography (3% MeOH in CH_2Cl_2) of the residue gave **9** (24.5 mg, 99%) as a solid: mp $234\text{--}237^\circ\text{C}$; IR (KBr) 2260 cm^{-1} (CN); UV(MeOH) λ_{max} 267 nm ($\epsilon 12700$), λ_{min} 235 nm ($\epsilon 5900$); ^1H NMR (DMSO-d_6 after addition of D_2O) δ 1.74 (3H d, $J_{5\text{-Me},6} = 1.2$ Hz, 5-Me), 3.74 (1H, d, $J_{\text{gem}} = 11.9$ Hz, H-5'), 3.79 (1H, d, $J_{\text{gem}} = 11.9$ Hz, H-5'), 6.33 (1H, dd, $J_{1',3'} = 1.3$, $J_{2',3'} = 5.8$ Hz, H-3'), 6.55 (1H, dd, $J_{1',2'} = 2.2$, $J_{2',3'} = 5.8$ Hz, H-2'), 7.03 (1H, dd, $J_{1',2'} = 2.2$, $J_{2',3'} = 1.3$ Hz, H-1'), 7.33 (1H, d, $J_{5\text{-Me},6} = 1.2$ Hz, H-6); FAB-MS (m/z) 250 ($M^+ + H$). *Anal.* Calcd for $\text{C}_{11}\text{H}_{11}\text{N}_3\text{O}_4 \cdot 1/5\text{CH}_2\text{Cl}_2$: C, 52.05; H, 4.44; N, 16.26. Found: C, 52.11; H, 3.90; N, 16.13.

ACKNOWLEDGMENTS

This work was financially supported in part by grants from the Japan Health Sciences Foundation (SA14718 to H. T.), Japan Society for the Promotion of Science (KAKENHI No. 15590100 to K. H. and No. 15590020 to H. T.), the Research Foundation of Pharmaceutical Sciences (to K. H.), and NIH USA (RO1 AI 38204 to Y.-C. C.).

REFERENCES

1. Haraguchi, K.; Takeda, S.; Tanaka, H. Ring opening of 4',5'-epoxynucleosides: a novel stereoselective entry to 4'-C-branched nucleosides. *Org. Lett.* **2003**, *5*, 1399.
2. Haraguchi, K.; Takeda, S.; Tanaka, H.; Nitanda, T.; Baba, M.; Dutschman, G.E.; Cheng, Y.-C. Synthesis of a highly active new anti-HIV agent 2',3'-didehydro-3'-deoxy-4'-ethynylthymidine. *Bioorg. Med. Chem. Lett.* **2003**, *13*, 3775–3777.
3. Sugimoto, I.; Shuto, S.; Mori, S.; Shigeta, S.; Matsuda, A. Synthesis of 4' α -branched thymidines as a new type of antiviral agent. *Bioorg. Med. Chem. Lett.* **1999**, *9*, 385.
4. Nomura, M.; Shuto, S.; Tanaka, M.; Sasaki, T.; Mori, S.; Shigeta, S.; Matsuda, A. Synthesis and biological activities of 4' α -C-branched-chain sugar pyrimidine nucleosides. *J. Med. Chem.* **1999**, *42*, 2901.
5. Ohnui, H.; Kohgo, S.; Kitano, K.; Sakata, S.; Kodama, E.; Yoshimura, K.; Matsuoka, M.; Shigeta, S.; Mitsuya, H. Synthesis of 4'-C-ethynyl β -arabino- and 4'-C-ethynyl-2'-deoxy- β -D-ribo-pentofuranosylpyrimidines and -purines and evaluation of their anti-HIV activity. *J. Med. Chem.* **2000**, *43*, 4516.
6. Kodama, E.; Kohgo, S.; Kitano, K.; Machida, H.; Gatanaga, H.; Shigeta, S.; Matsuoka, M.; Ohnui, H.; Mitsuya, H. 4'-Ehtynyl nucleoside analogues: potent inhibitors of multidrug-resistant human immunodeficiency virus variant in vitro. *Antimicrob. Agents Chemother.* **2001**, *45*, 1539.
7. Maag, H.; Rydzewski, R.M.; McRoberts, M.J.; Crawford-Ruth, D.; Verheyden,



- J.P.H.; Prisbe, E.J. Synthesis and anti-HIV activity of 4'-azido- and 4'-methoxy-nucleosides. *J. Med. Chem.* **1992**, 35, 1440.
8. Waga, T.; Ohnishi, H.; Meguro, H. Synthesis and biological evaluation of 4'-C-methyl nucleosides. *Nucleosides Nucleotides* **1996**, 15, 287.
9. O-Yang, C.; Wu, H.Y.; Fraser-Smith, E.B.; Walker, K. Synthesis of 4'-C-cyanothymidine and analogs as potent inhibitors of HIV. *A. M.. Tetrahedron Lett.* **1992**, 33, 37.
10. Haraguchi, K.; Tanaka, H.; Itoh, Y.; Yamaguchi, K.; Miyasaka, T. Allylic substitution of 3',4'-unsaturated nucleosides: organosilicon-based stereoselective access to 4'-C-branched 2',3'-didehydro-2',3'-dideoxyribonucleosides. *J. Org. Chem.* **1996**, 61, 851.
11. Codington, J.F.; Fecher, R.; Fox, J.J. Synthesis of 3'-amino-3'-deoxy-arabinosyl-uracil via 2',3'-epoxy-lyxosyl nucleosides. *J. Org. Chem.* **1962**, 27, 163.
12. Haraguchi, K.; Tanaka, H.; Maeda, H.; Itoh, Y.; Saito, S.; Miyasaka, T. Selenoxide elimination for the synthesis of unsaturated-sugar uracil nucleosides. *J. Org. Chem.* **1991**, 56, 5401.
13. Lin, T.S.; Luo, M.Z.; Liu, M.C.; Pai, S.B.; Dutschman, G.E.; Cheng, Y.C. Antiviral activity of 2',3'-dideoxy- β -L-5-fluorocytidine (β -L-FddC) and 2',3'-dideoxy- β -L-cytidine (β -L-ddC) against hepatitis B virus and human immunodeficiency virus type 1 in vitro. *Biochem. Pharmacol.* **1994**, 47, 171.

Received November 25, 2003

Accepted December 1, 2003



Request Permission or Order Reprints Instantly!

Interested in copying and sharing this article? In most cases, U.S. Copyright Law requires that you get permission from the article's rightsholder before using copyrighted content.

All information and materials found in this article, including but not limited to text, trademarks, patents, logos, graphics and images (the "Materials"), are the copyrighted works and other forms of intellectual property of Marcel Dekker, Inc., or its licensors. All rights not expressly granted are reserved.

Get permission to lawfully reproduce and distribute the Materials or order reprints quickly and painlessly. Simply click on the "Request Permission/Order Reprints" link below and follow the instructions. Visit the [U.S. Copyright Office](#) for information on Fair Use limitations of U.S. copyright law. Please refer to The Association of American Publishers' (AAP) website for guidelines on [Fair Use in the Classroom](#).

The Materials are for your personal use only and cannot be reformatted, reposted, resold or distributed by electronic means or otherwise without permission from Marcel Dekker, Inc. Marcel Dekker, Inc. grants you the limited right to display the Materials only on your personal computer or personal wireless device, and to copy and download single copies of such Materials provided that any copyright, trademark or other notice appearing on such Materials is also retained by, displayed, copied or downloaded as part of the Materials and is not removed or obscured, and provided you do not edit, modify, alter or enhance the Materials. Please refer to our [Website User Agreement](#) for more details.

[Request Permission/Order Reprints](#)

Reprints of this article can also be ordered at

<http://www.dekker.com/servlet/product/DOI/101081NCN120030721>